In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $35.54 in the prior trading day, Dianthus Therapeutics Inc (NASDAQ: DNTH) closed at $36.2, up 1.84%. In other words, the price has increased by $1.84 from its previous closing price. On the day, 0.53 million shares were traded. DNTH stock price reached its highest trading level at $36.785 during the session, while it also had its lowest trading level at $34.6.
Ratios:
Our goal is to gain a better understanding of DNTH by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.12 and its Current Ratio is at 13.12. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Truist on October 14, 2025, initiated with a Buy rating and assigned the stock a target price of $56.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 09 ’25 when Savitz Ryan sold 20,000 shares for $35.00 per share. The transaction valued at 700,000 led to the insider holds 0 shares of the business.
RYAN SAVITZ bought 20,000 shares of DNTH for $636,000 on Sep 09 ’25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNTH now has a Market Capitalization of 1441347328 and an Enterprise Value of 909159104. For the stock, the TTM Price-to-Sale (P/S) ratio is 297.19 while its Price-to-Book (P/B) ratio in mrq is 3.84. Its current Enterprise Value per Revenue stands at 187.301 whereas that against EBITDA is -7.004.
Stock Price History:
The Beta on a monthly basis for DNTH is 1.59, which has changed by 0.26828396 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, DNTH has reached a high of $40.16, while it has fallen to a 52-week low of $13.36. The 50-Day Moving Average of the stock is 19.30%, while the 200-Day Moving Average is calculated to be 58.18%.
Shares Statistics:
The stock has traded on average 647.38K shares per day over the past 3-months and 634130 shares per day over the last 10 days, according to various share statistics. A total of 32.18M shares are outstanding, with a floating share count of 29.04M. Insiders hold about 27.05% of the company’s shares, while institutions hold 86.24% stake in the company. Shares short for DNTH as of 1759190400 were 4959621 with a Short Ratio of 7.66, compared to 1756425600 on 5579726. Therefore, it implies a Short% of Shares Outstanding of 4959621 and a Short% of Float of 14.610000000000001.
Earnings Estimates
Investors are keenly observing as 6 analysts analyze and rate. The current performance of Dianthus Therapeutics Inc (DNTH) in the stock market.The consensus estimate for the next quarter is -$0.87, with high estimates of -$0.75 and low estimates of -$1.09.
Analysts are recommending an EPS of between -$3.3 and -$3.83 for the fiscal current year, implying an average EPS of -$3.5. EPS for the following year is -$3.63, with 5.0 analysts recommending between -$3.05 and -$4.47.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for DNTH’s current fiscal year. The highest revenue estimate was $5.03M, while the lowest revenue estimate was $1.36M, resulting in an average revenue estimate of $2.52M. In the same quarter a year ago, actual revenue was $6.24M
